2014 Concludes with multiple accolades for Genelex
The year 2014 ended on a positive note for Genelex, with multiple publications bestowing the company with six awards or accolades for business growth and technological advancement.
In November, Inc. magazine included the Seattle-based company at the number 10 spot in its list of the top-10 fastest-growing private companies in Seattle. Genelex was the only healthcare software and genetic testing company included on the list.
“I could not be prouder of our team at Genelex, who works tirelessly every day to provide patients with the safest and most effective medicine that science can currently give them,” said Genelex Chief Operating Officer Kristine Ashcraft.
“It is gratifying to know that our dedication to our mission is being rewarded with such stellar growth.”
In September, Seattle Business magazine recognized Genelex’s progress toward eliminating adverse drug events with a silver award in the health category of the magazine’s 2014 Tech Impact Awards.
“The company’s effectiveness in tackling [adverse drug events] has made it one of the fastest growing private companies in the Puget Sound region – and perhaps one of the most beneficial, Seattle Business editors wrote in their October edition”
In October, the Puget Sound Business Journal ranked Genelex 47th in its 2014 list of the fastest growing Washington companies. It was Genelex’s third inclusion on the prestigious list since 1995, and second consecutive listing.
Earlier in 2014, Genelex was also included on Inc. magazine’s list of the 5,000 fastest growing private companies in the U.S. at number 1,104 and ranked at the 35th spot on Seattle Business magazine’s 2014 list of the best midsize Washington companies to work for.
Take a Risk Assessment
Simply enter the medications you’re currently on or plan to take. Click “Get Results” to see if your regimen puts you at risk for an adverse drug reaction.
YOUR GENELEX RISK ASSESSMENT RESULTS: